Trial Profile
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Imetelstat (Primary) ; Bevacizumab; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 07 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Apr 2011 Recruitment into the trial is progressing ahead of schedule according to a Geron Corporation media release.
- 10 Mar 2011 Additional lead trial investigator (Kathy Miller, MD) identified as reported by ClinicalTrials.gov.